178 results
Page 2 of 9
8-K
EX-99.1
okzme
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.2
4uj7g0q1rju 978f6
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.1
bxit099pyllupc8ejt0
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
EX-99.2
va3j5209 yndf
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
hl7c 8mtg0y8a
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
424B5
hhusc73y606yvs
29 Aug 22
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.2
6c4ufkkcs3n8dfu
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.1
qeca xwj3k
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
8-K
EX-99.2
3md2ib
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.1
kc4blh
10 May 22
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
4:47pm
8-K
EX-99.1
9x8airawel2e
11 Apr 22
Other Events
3:13pm
8-K
EX-99.1
1cekfo
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm
8-K
EX-99.2
8xaxml5n0uu gsbp1ryd
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm